157 related articles for article (PubMed ID: 23768205)
1. Preventative vaccine-loaded mannosylated chitosan nanoparticles intended for nasal mucosal delivery enhance immune responses and potent tumor immunity.
Yao W; Peng Y; Du M; Luo J; Zong L
Mol Pharm; 2013 Aug; 10(8):2904-14. PubMed ID: 23768205
[TBL] [Abstract][Full Text] [Related]
2. Mannosylated protamine as a novel DNA vaccine carrier for effective induction of anti-tumor immune responses.
Zeng Z; Dai S; Jiao Y; Jiang L; Zhao Y; Wang B; Zong L
Int J Pharm; 2016 Jun; 506(1-2):394-406. PubMed ID: 27106528
[TBL] [Abstract][Full Text] [Related]
3. Mannosylated Chitosan Nanoparticles Based Macrophage-Targeting Gene Delivery System Enhanced Cellular Uptake and Improved Transfection Efficiency.
Peng Y; Yao W; Wang B; Zong L
J Nanosci Nanotechnol; 2015 Apr; 15(4):2619-27. PubMed ID: 26353473
[TBL] [Abstract][Full Text] [Related]
4. Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity.
Cui Z; Han D; Sun X; Zhang M; Feng X; Sun C; Gu J; Tong C; Lei L; Han W
Appl Microbiol Biotechnol; 2015 Jan; 99(2):667-80. PubMed ID: 25381907
[TBL] [Abstract][Full Text] [Related]
5. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
[TBL] [Abstract][Full Text] [Related]
6. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
Gupta NK; Tomar P; Sharma V; Dixit VK
Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
[TBL] [Abstract][Full Text] [Related]
7. Eudragit® L100-coated mannosylated chitosan nanoparticles for oral protein vaccine delivery.
Xu B; Zhang W; Chen Y; Xu Y; Wang B; Zong L
Int J Biol Macromol; 2018 Jul; 113():534-542. PubMed ID: 29408613
[TBL] [Abstract][Full Text] [Related]
8. Strong humoral response elicited by a DNA vaccine targeting gastrin-releasing peptide with optimized adjuvants inhibits murine prostate carcinoma growth in vivo.
Lu Y; Mekoo DJ; Ouyang K; Hu X; Liu Y; Lin M; Jin L; Cao R; Li T; Zhang Y; Fan H; Liu J
Endocr Relat Cancer; 2009 Dec; 16(4):1171-84. PubMed ID: 19648182
[TBL] [Abstract][Full Text] [Related]
9. Development and Optimization of Chitosan Nanoparticle-Based Intranasal Vaccine Carrier.
Gao X; Liu N; Wang Z; Gao J; Zhang H; Li M; Du Y; Gao X; Zheng A
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011436
[TBL] [Abstract][Full Text] [Related]
10. The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization.
Jiang HL; Kang ML; Quan JS; Kang SG; Akaike T; Yoo HS; Cho CS
Biomaterials; 2008 Apr; 29(12):1931-9. PubMed ID: 18221992
[TBL] [Abstract][Full Text] [Related]
11. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice.
Vila A; Sánchez A; Janes K; Behrens I; Kissel T; Vila Jato JL; Alonso MJ
Eur J Pharm Biopharm; 2004 Jan; 57(1):123-31. PubMed ID: 14729088
[TBL] [Abstract][Full Text] [Related]
12. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B.
Khatri K; Goyal AK; Gupta PN; Mishra N; Vyas SP
Int J Pharm; 2008 Apr; 354(1-2):235-41. PubMed ID: 18182259
[TBL] [Abstract][Full Text] [Related]
13. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
Amidi M; Romeijn SG; Verhoef JC; Junginger HE; Bungener L; Huckriede A; Crommelin DJ; Jiskoot W
Vaccine; 2007 Jan; 25(1):144-53. PubMed ID: 16973248
[TBL] [Abstract][Full Text] [Related]
14. Foot and Mouth Disease virus-loaded fungal chitosan nanoparticles for intranasal administration: impact of formulation on physicochemical and immunological characteristics.
Tajdini F; Amini MA; Mokarram AR; Taghizadeh M; Azimi SM
Pharm Dev Technol; 2014 May; 19(3):333-41. PubMed ID: 23590209
[TBL] [Abstract][Full Text] [Related]
15. Intranasal immunization with chitosan/pCETP nanoparticles inhibits atherosclerosis in a rabbit model of atherosclerosis.
Yuan X; Yang X; Cai D; Mao D; Wu J; Zong L; Liu J
Vaccine; 2008 Jul; 26(29-30):3727-34. PubMed ID: 18524427
[TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system(s) administered intranasally.
Mangal S; Pawar D; Garg NK; Jain AK; Vyas SP; Rao DS; Jaganathan KS
Vaccine; 2011 Jul; 29(31):4953-62. PubMed ID: 21575664
[TBL] [Abstract][Full Text] [Related]
17. Immunological evaluation of mannosylated chitosan nanoparticles based foot and mouth disease virus DNA vaccine, pVAC FMDV VP1-OmpA in guinea pigs.
Nanda RK; Hajam IA; Edao BM; Ramya K; Rajangam M; Chandra Sekar S; Ganesh K; Bhanuprakash V; Kishore S
Biologicals; 2014 May; 42(3):153-9. PubMed ID: 24656961
[TBL] [Abstract][Full Text] [Related]
18. [Construction of recombinant house dust mite group 1 allergen vaccine and study on immune response induced by nasal immunization].
Shi WD; Cao W; Liu Y; Xu Y; Tao ZZ; Dai Q
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2013 Jan; 48(1):26-31. PubMed ID: 23656812
[TBL] [Abstract][Full Text] [Related]
19. Intranasal Administration of Novel Chitosan Nanoparticle/DNA Complexes Induces Antibody Response to Hepatitis B Surface Antigen in Mice.
Lebre F; Borchard G; Faneca H; Pedroso de Lima MC; Borges O
Mol Pharm; 2016 Feb; 13(2):472-82. PubMed ID: 26651533
[TBL] [Abstract][Full Text] [Related]
20. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles.
Borges O; Cordeiro-da-Silva A; Tavares J; Santarém N; de Sousa A; Borchard G; Junginger HE
Eur J Pharm Biopharm; 2008 Jun; 69(2):405-16. PubMed ID: 18364251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
